-

Pfizer Declares Third-Quarter 2020 Dividend

Board of Directors approves quarterly cash dividend of $0.38 per share

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent third-quarter 2020 dividend on the company’s common stock, payable September 1, 2020, to holders of the Common Stock of record at the close of business on July 31, 2020. The third-quarter 2020 cash dividend will be the 327th consecutive quarterly dividend paid by Pfizer.

Pfizer Inc.: Breakthroughs that change patients’ lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Contacts

Pfizer Media:
Amy Rose
(212) 733-7410
Amy.Rose@pfizer.com

Pfizer Investor:
Ryan Crowe
(212) 733-8160
Ryan.Crowe@pfizer.com

Pfizer Inc.

NYSE:PFE

Release Versions

Contacts

Pfizer Media:
Amy Rose
(212) 733-7410
Amy.Rose@pfizer.com

Pfizer Investor:
Ryan Crowe
(212) 733-8160
Ryan.Crowe@pfizer.com

More News From Pfizer Inc.

Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment with anti-CD38 therapy (daratumumab or isatuximab) and lenalidomide. At the pre-specified interim analysis for efficacy, the study met its primary endpoint of progression-free survival (PFS) as assessed by blinded ind...

Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (PC) with homologous recombination repair (HRR) gene mutations, including both BRCA and non-BRCA mutations. mAPMN/S is also known as metastatic hormone-sensitive prostate cancer...

Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. In the study, a four-dose series of 25vPnC elicited robust immune responses against all 25 serotypes and showed safety and tolerability comparable to four doses of PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine). These findings were shared today...
Back to Newsroom